News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases
Tuesday, September 20, 2022GENFIT a latestage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases today announced it has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights o...
Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS)
Thursday, September 15, 2022Mallinckrodt plc a global specialty pharmaceutical company today announced that the US Food and Drug Administration FDA approved Terlivaz terlipressin for injection Terlivaz is the first and only FDAapproved product indicated to improve kidney functi...
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
Thursday, September 15, 2022QIAGEN and Neuron Inc an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases today announced the signing of an agreement to develop a companion diagnostic for Neu...
Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR
Wednesday, September 14, 2022Ensysce Biosciences Inc a clinicalstage biotech company applying transformative chemistry to improve prescription drug safety and Quotient Sciences a drug development and manufacturing accelerator has announced a partnership to support the developmen...
MD Anderson and Radiopharm Theranostics Launch Joint Venture to Develop Novel Radiopharmaceuticals
Wednesday, September 14, 2022The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Limited announced the launch of Radiopharm Ventures LLC a joint venture company created to develop novel radiopharmaceutical therapeutic products for cancer Radiopharm Vent...
MagBio Receives 510(k) Clearance and CE Mark for MagXtract Collection Tube For COVID-19 Testing
Tuesday, September 13, 2022MagBio Genomics Inc a global company focused on magnetic beadbased products for molecular diagnostics and liquid biopsy genomic research announced US Food and Drug Administration FDA k clearance CE Mark approval and global launch of its MagXtract Col...
KCAS Expands Its Transatlantic Presence with the Acquisition of France-based Active Biomarkers
Tuesday, September 13, 2022KCAS Bioanalytical and Biomarker Services KCAS a leading bioanalytical contract research organization CRO backed by Vitruvian Partners closed the purchase of Active Biomarkers located in Lyon France Active Biomarkers is a renowned assay development a...
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche
Thursday, September 08, 2022Good Therapeutics a privately held company today announced it has entered into a definitive merger agreement to be acquired by Roche With this acquisition Roche will gain rights to Good Therapeutics innovative conditionally active PDregulated IL prog...
Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer
Thursday, September 08, 2022Mirati Therapeutics Inc a clinicalstage targeted oncology company today announced results from KRYSTAL a multicohort Phase study evaluating adagrasib with or without cetuximab in patients with advanced CRC harboring a KRASGC mutation These exciting...
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
Wednesday, September 07, 2022Charles River Laboratories International Inc and Cure AP a nonprofit foundation dedicated to raising funds and awareness about AdapterProtein Hereditary Spastic Paraplegia AP HSP today announced a manufacturing collaboration Charles River a contract...
